Nivolumab vs Trastuzumab

## Nivolumab vs Trastuzumab: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Trastuzumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

**Trastuzumab**: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Trastuzumab — 28 days.

## Chemical Properties

**Type**: Nivolumab — Antibody; Trastuzumab — Antibody.